Abstract
Gene therapy with viral vectors, such as adenovirus (Ad), targeted to the human epidermal growth factor receptors 3 and 4 (HER3/4) are potentially useful for cancer therapy. Testing the expression of a reporter gene from these viruses in target cells is essential to determine functionality of the targeted virus. A competition assay with a relevant ligand (heregulin, HRG) can provide convincing evidence that blocking binding to the HER3/4 receptor results in decreased reporter gene expression. Labeling individual viruses with a fluorescent molecule allows examination of the targeted virus in specific steps in the infection. Virus internalization into cell lines can be determined using antibody-labeled receptors, and the virus colocalization with receptors can also be visualized. Characterization of a targeted virus in this fashion is important to demonstrate that the targeting of the virus functions in an expected manner, and provides support for larger-scale testing of the virus. Information acquired in these experiments may also be useful to inform and improve on the design of future targeted viruses.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Mujoo K, Choi B-K, Huang Z, Zhang N, An Z (2014) Regulation of ERBB3/HER3 signaling in cancer. Oncotarget 5(21):10222–10236
Sithanandam G, Anderson LM (2008) The ERBB3 receptor in cancer and cancer gene therapy. Cancer Gene Ther 15(7):413–448
Sergina NV, Moasser MM (2007) The HER family and cancer: emerging molecular mechanisms and therapeutic targets. Trends Mol Med 13(12):527–534
Koutras AK, Fountzilas G, Kalogeras KT, Starakis I, Iconomou G, Kalofonos HP (2010) The upgraded role of HER3 and HER4 receptors in breast cancer. Crit Rev Oncol Hematol 74(2):73–78
Sassen A, Diermeier-Daucher S, Sieben M, Ortmann O, Hofstaedter F, Schwarz S et al (2009) Presence of HER4 associates with increased sensitivity to Herceptinâ„¢ in patients with metastatic breast cancer. Breast Cancer Res 11(4):R50
Okazaki S, Nakatani F, Masuko K, Tsuchihashi K, Ueda S, Masuko T et al (2016) Development of an ErbB4 monoclonal antibody that blocks neuregulin-1-induced ErbB4 activation in cancer cells. Biochem Biophys Res Commun 470(1):239–244
MacLeod SH, Elgadi MM, Bossi G, Sankar U, Pisio A, Agopsowicz K et al (2012) HER3 targeting of adenovirus by fiber modification increases infection of breast cancer cells in vitro, but not following intratumoral injection in mice. Cancer Gene Ther 19(12):888–898
Wiley J and Sons (2016) Vectors used in gene therapy clinical trials. http://www.wiley.com/legacy/wileychi/genmed/clinical/. Accessed 22 Jun 2016
Berk AJ (2013) Adenoviridae. In: Knipe DM, Howley P (eds) Fields virology, 6th edn. Lipincott, Williams & Wilkins, Philadelphia, p 2664
Wold WSM, Toth K (2013) Adenovirus vectors for gene therapy, vaccination and cancer gene therapy. Curr Gene Ther 13(6):421–433
Bett AJ, Haddara W, Prevec L, Graham FL (1994) An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc Natl Acad Sci U S A 91(19):8802–8806
Danthinne X, Imperiale MJ (2000) Production of first generation adenovirus vectors: a review. Gene Ther 7(20):1707–1714
Yoon A-R, Hong J, Kim SW, Yun C-O (2016) Redirecting adenovirus tropism by genetic, chemical, and mechanical modification of the adenovirus surface for cancer gene therapy. Expert Opin Drug Deliv 13(6):843–858
Kasala D, Choi J-W, Kim SW, Yun C-O (2014) Utilizing adenovirus vectors for gene delivery in cancer. Expert Opin Drug Deliv 11(3):379–392
Capasso C, Garofalo M, Hirvinen M, Cerullo V (2014) The evolution of adenoviral vectors through genetic and chemical surface modifications. Viruses 6(2):832–855
Chaurasiya S, Hew P, Crosley P, Sharon D, Potts K, Agopsowicz K et al (2016) Breast cancer gene therapy using an adenovirus encoding human IL-2 under control of mammaglobin promoter/enhancer sequences. Cancer Gene Ther 23(6):178–187
Zhang J-F, Wei F, Wang H-P, Li H-M, Qiu W, Ren P-K et al (2010) Potent anti-tumor activity of telomerase-dependent and HSV-TK armed oncolytic adenovirus for non-small cell lung cancer in vitro and in vivo. J Exp Clin Cancer Res 29:52
Irving J, Wang Z, Powell S, O’Sullivan C, Mok M, Murphy B et al (2004) Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity. Cancer Gene Ther 11(3):174–185
Sadeghi H, Hitt MM (2005) Transcriptionally targeted adenovirus vectors. Curr Gene Ther 5(4):411–427
Matsumoto K, Shariat SF, Ayala GE, Rauen KA, Lerner SP (2005) Loss of coxsackie and adenovirus receptor expression is associated with features of aggressive bladder cancer. Urology 66(2):441–446
Miller CR, Buchsbaum DJ, Reynolds PN, Douglas JT, Gillespie GY, Mayo MS et al (1998) Differential susceptibility of primary and established human glioma cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer. Cancer Res 58(24):5738–5748
Dmitriev I, Krasnykh V, Miller CR, Wang M, Kashentseva E, Mikheeva G et al (1998) An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 72(12):9706–9713
Douglas JT, Kim M, Sumerel LA, Carey DE, Curiel DT (2001) Efficient oncolysis by a replicating adenovirus (ad) in vivo is critically dependent on tumor expression of primary ad receptors. Cancer Res 61(3):813–817
van Beusechem VW, Grill J, Mastenbroek DCJ, Wickham TJ, Roelvink PW, Haisma HJ et al (2002) Efficient and selective gene transfer into primary human brain tumors by using single-chain antibody-targeted adenoviral vectors with native tropism abolished. J Virol 76(6):2753–2762
Kashentseva EA, Seki T, Curiel DT, Dmitriev IP (2002) Adenovirus targeting to c-erbB-2 oncoprotein by single-chain antibody fused to trimeric form of adenovirus receptor ectodomain. Cancer Res 62(2):609–616
Dmitriev I, Kashentseva E, Rogers BE, Krasnykh V, Curiel DT (2000) Ectodomain of coxsackievirus and adenovirus receptor genetically fused to epidermal growth factor mediates adenovirus targeting to epidermal growth factor receptor-positive cells. J Virol 74(15):6875–6884
Lord R, Parsons M, Kirby I, Beavil A, Hunt J, Sutton B et al (2006) Analysis of the interaction between RGD-expressing adenovirus type 5 fiber knob domains and alphavbeta3 integrin reveals distinct binding profiles and intracellular trafficking. J Gen Virol 87(Pt 9):2497–2505
Kurachi S, Koizumi N, Sakurai F, Kawabata K, Sakurai H, Nakagawa S et al (2007) Characterization of capsid-modified adenovirus vectors containing heterologous peptides in the fiber knob, protein IX, or hexon. Gene Ther 14(3):266–274
Krasnykh V, Dmitriev I, Mikheeva G, Miller CR, Belousova N, Curiel DT (1998) Characterization of an adenovirus vector containing a heterologous peptide epitope in the HI loop of the fiber knob. J Virol 72(3):1844–1852
Piao Y, Jiang H, Alemany R, Krasnykh V, Marini FC, Xu J et al (2009) Oncolytic adenovirus retargeted to Delta-EGFR induces selective antiglioma activity. Cancer Gene Ther 16(3):256–265
Koizumi N, Mizuguchi H, Utoguchi N, Watanabe Y, Hayakawa T (2003) Generation of fiber-modified adenovirus vectors containing heterologous peptides in both the HI loop and C terminus of the fiber knob. J Gene Med 5(4):267–276
Magnusson MK, Henning P, Myhre S, Wikman M, Uil TG, Friedman M et al (2007) Adenovirus 5 vector genetically re-targeted by an affibody molecule with specificity for tumor antigen HER2/neu. Cancer Gene Ther 14(5):468–479
Dmitriev IP, Kashentseva EA, Curiel DT (2002) Engineering of adenovirus vectors containing heterologous peptide sequences in the C terminus of capsid protein IX. J Virol 76(14):6893–6899
Poulin KL, Lanthier RM, Smith AC, Christou C, Risco Quiroz M, Powell KL et al (2010) Retargeting of adenovirus vectors through genetic fusion of a single-chain or single-domain antibody to capsid protein IX. J Virol 84(19):10074–10086
Vigne E, Mahfouz I, Dedieu JF, Brie A, Perricaudet M, Yeh P (1999) RGD inclusion in the hexon monomer provides adenovirus type 5-based vectors with a fiber knob-independent pathway for infection. J Virol 73(6):5156–5161
Campos SK, Barry MA (2004) Rapid construction of capsid-modified adenoviral vectors through bacteriophage lambda red recombination. Hum Gene Ther 15(11):1125–1130
Coughlan L, Alba R, Parker AL, Bradshaw AC, McNeish IA, Nicklin SA et al (2010) Tropism-modification strategies for targeted gene delivery using adenoviral vectors. Viruses 2(10):2290–2355
Soboleski MR, Oaks J, Halford WP (2005) Green fluorescent protein is a quantitative reporter of gene expression in individual eukaryotic cells. FASEB J 19(3):440–442
Smale ST (2010) Luciferase assay. Cold Spring Harb Protoc. doi:10.1101/pdb.prot5421
Sato A, Klaunberg B, Tolwani R (2004) In vivo bioluminescence imaging BLI : an overview. Comp Med 54(6):631–634
Potts KG, Favis NA, Pink DB, Vincent KM, Lewis JD, Moore RB, Hitt MM, Evans D (2017) Oncolytic vaccinia virus F4L (ribonucleotide reductase) mutants promote anti-tumor immunity with superior safety in bladder cancer models. EMBO Mol Med 9(5):638–654
Hoganson DK, Sosnowski BA, Pierce GF, Doukas J (2001) Uptake of adenoviral vectors via fibroblast growth factor receptors involves intracellular pathways that differ from the targeting ligand. Mol Ther 3(1):105–112
Meulenbroek RA, Sargent KL, Lunde J, Jasmin BJ, Parks RJ (2004) Use of adenovirus protein IX (pIX) to display large polypeptides on the virion–generation of fluorescent virus through the incorporation of pIX-GFP. Mol Ther 9(4):617–624
Rogée S, Grellier E, Bernard C, Loyens A, Beauvillain J-C, D’halluin J-C et al (2007) Intracellular trafficking of a fiber-modified adenovirus using lipid raft/caveolae endocytosis. Mol Ther 15(11):1963–1972
Leopold PL, Ferris B, Grinberg I, Worgall S, Hackett NR, Crystal RG (1998) Fluorescent virions: dynamic tracking of the pathway of adenoviral gene transfer vectors in living cells. Hum Gene Ther 9(3):367–378
MacLeod SH (2013) Binding, internalization, and transgene expression of an adenoviral vector retargeted to HER3/4. Dissertation, University of Alberta
Evans RK, Nawrocki DK, Isopi LA, Williams DM, Casimiro DR, Chin S et al (2004) Development of stable liquid formulations for adenovirus-based vaccines. J Pharm Sci 93(10):2458–2475
Public Health Agency of Canada (2015) Canadian biosafety standard. Public Health Agency of Canada, Ottawa, p 151
Parks RJ, Chen L, Anton M, Sankar U, Rudnicki MA, Graham FL (1996) A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc Natl Acad Sci U S A 93(24):13565–13570
National Research Council (US) Committee on Methods of Producing Monoclonal Antibodies (1999) In vitro production of monoclonal antibody. In: Monoclonal antibody production. National Academies Press (US), Washington (DC)
Condit RC (2001) Principles of virology. In: Knipe DK, Howley PM (eds) Fields virology, 4th edn. Lippincott-Raven, Philadelphia, USA, p 3280
Bilbao G, Contreras JL, Gomez-Navarro J, Curiel DT (1998) Improving adenoviral vectors for cancer gene therapy. Tumor Target 1(3):59–79
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Science+Business Media LLC
About this protocol
Cite this protocol
MacLeod, S.H., Potts, K.G., Chaurasiya, S., Hitt, M.M. (2017). Assessment of Specificity of an Adenovirus Targeted to HER3/4. In: Wang, Z. (eds) ErbB Receptor Signaling. Methods in Molecular Biology, vol 1652. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-7219-7_18
Download citation
DOI: https://doi.org/10.1007/978-1-4939-7219-7_18
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-7218-0
Online ISBN: 978-1-4939-7219-7
eBook Packages: Springer Protocols